Jazz Pharma Begins Trial of IV Administered Erwinaze
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze^® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.